Recent advances in the treatment of leprosy

Dermatology Online Journal

Volumn 9, Issue 2, 2003, Pages 58-77

  Ishii, Norihisa ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CLARITHROMYCIN; CLOFAZIMINE; DAPSONE; MINOCYCLINE; OFLOXACIN; RIFAMPICIN; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; BACTERIOLYSIS; BCG VACCINATION; CLINICAL FEATURE; CLINICAL PROTOCOL; DEFORMITY; DISABILITY; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; DRUG MONITORING; DRY SKIN; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; LABORATORY TEST; LEPROSY; LEPROSY CONTROL; MULTIBACILLARY LEPROSY; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NERVE INJURY; NEUROPATHY; PAUCIBACILLARY LEPROSY; POLYPHARMACY; RELAPSE; REVIEW; SKIN DISCOLORATION; SPECIES COMPARISON; TREATMENT WITHDRAWAL; XEROSIS;

EID: 3042543609     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Sasaki S, Takeshita F, Okuda K, Ishii N. Mycobacterium leprae and leprosy: a compendium. Microbiol Immunol 2001; 45: 729-36.
2. Ishii N, Onoda M, Sugita Y, Tomoda M, Ozaki M. Survey of newly diagnosed leprosy patients in native and foreign residents of Japan. Int. J. Lepr 2000; 68: 172-6.
3. World Health Organization. 1991. World Health Assembly - Resolution WHA44.9. WHO.
4. World Health Organization. 2000. Leprosy - Global situation. Weekly epidemiological record 2000; 75: 225-232.
5. Ridley DS, Jopling WH. Classification of leprosy according to immunity - A five group system. Int J Lepr 1966; 54: 255-73.
6. Sugita Y, Suga C, Ishii N, Nakajima H. A case of relapsed leprosy successfully treated with sparfloxacin. Arch Dermatol 1996; 132: 1397-1398.
7. Ishii N, Sugita Y, Sato I, Nakajima H: Sparfloxacin in the treatment of leprosy patients. Int J Dermatol 1997; 36: 619-621.
8. WHO model prescribing information - drug used in leprosy, WHO/DMP/DSI/98.1, WHO, Geneva (1998).
9. Chemotherapy of leprosy for control programmes. WHO Technical report series 675, WHO, Geneva (1982).
10. WHO expert committee on leprosy, sixth report. WHO Technical report series 768, WHO, Geneva (1988).
11. Chemotherapy of leprosy, Report of a WHO study group. WHO Technical report series 847, WHO, Geneva (1994).
12. A guide to eliminating leprosy as a public health problem, 1st edition, WHO/LEP/95.1, WHO, Geneva (1995).
13. WHO expert committee on leprosy, seventh report. Technical report series 874, WHO, Geneva (1998).
14. Peters JH, Gordon GR, Murray JF, Levy L. Minimal inhibitory concentration of dapsone for Mycobacterium leprae in rats. Antimicrob Agents and Chemother 1975; 8: 551-7.
15. Ahmad RA and Rogers HJ: Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method. Eur J Clin. Pharmacol 1980; 17: 129-33.
16. Schaad-Lanyi Z, Dieterle W, Dubois JP, Theobald W and Vischer W: Pharmcokinetics of clofazimine in healthy volunteers. Int J Lepr 1987; 55: 9-15.
17. Morrison NE and Marley GM: Clofazimine binding studies with deoxyribonucleic acid. Int. J. Lepr 1976; 44: 475-81.
18. Nakashima M, Uematsu T, Kanamaru M, Okazaki O, Hakusui H. Phase I study of levofloxacin, (s)-(-)-ofloxacin. Jpn J Clin Pharmcol Ther 1992; 23: 515-21.
19. Fajardo TT, Villahermosa LG, Cruz EC, Abalos RM, Franzblau SG, Walsh GP. Minocycline in lepromatous leprosy. Int J Lepr 1995; 63: 8-17.
20. Visschedijk J, van de Broek J, Eggens H, Lever P, van Beers S, Klatser P. Mycobacterium leprae-millennium resistant! Leprosy control on the threshold of a new era. Trop Med Int Health 2000; 5: 388-99.
21. Helmy HS, Pearson JMH and Waters MFR: Treatment of moderately severe erythema nodosum leprosum with clofazimine-a controlled trial. Lepr Rev 1971; 42: 167-77.
22. Gidoh M, Tsutsumi S, Funazu T, Koide S and Narita S: On characteristic antiinflammatory effects of several antileprosy drugs. Jap J Lepr 1979; 48: 7-18.
23. Rook GA., Baker R. Cortisol metabolism, cortisol sensitivity and the pathogenesis of leprosy reactions. Trop Med Int Health 1999; 4: 493-8.
24. Jacobson RR, Krahenbuhl JL. Leprosy. Lancet 1999; 353: 655-60.
25. Dasananjali K, Schreuder PAM, Pirayavaraporn C. A study on the effectiveness and safety of the WHO-MDT regimen in North East Thailand: a prospective study, 1984-1996. Int J Leor 1997; 65: 28-36.
26. Li HY, Hu LF, Huang WB, Liu GC, Yuan LC, Jin Z, et al. Risk of relapse after fixed duration MDT. Int J Lepr 1997; 65: 238-45.
27. Schreuder PAM. The occurrence of reactions and impairments in leprosy: experience in the Leprosy Control Programme of three provinces in Northeastern Thailand, 1978-1995. I. Overview of the study. Int J Lepr 1998; 66: 149-58.
28. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev 2000; 71: 144-53.
29. Gebre S, Saunderson P, Byass P. Relapse after fixed duration multidrug therapy: the AMFES cohort. Lepr Rev 2000; 71: 325-31.
30. Jesudasan K, Christian M, Kavitha M. Long term follow-up of multibacillary patients with high BI treated with WHO-MDT regimen for a fixed duration of two years. Int J Lepr 2000; 68: 405-9.
31. Milanga M, Kashala LO, Mbayo I, Yajima M, Yamada N, Mbowa KR, Asano G. Brief survey of leprosy situation in Congo: sero-epidemiologic profile in correlation with some emerging viral infections. Jpn J Lepr 1999; 68: 109-16.
32. Lockwood DNJ, Sinha HH. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr 1999; 67: 6-12.
33. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 1996; 348: 17-24.
34. Bertolli J, Pangi C, Frerichs R, Halloran ME. A case-control study of the effectiveness of BCG vaccine for preventing leprosy in Yangon, Myanmar. Int J Epidemiol 1997; 26: 888-96.
35. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409: 1007-11.